RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.

Add to Collection
2017 May Others Fist_Author_Year_PM

Full Author : ['Ahren, Bo', 'Masmiquel, Luis', 'Kumar, Harish', 'Sargin, Mehmet', 'Karsbol, Julie Derving', 'Jacobsen, Sanja Hald', 'Chow, Francis']
Journal Title : The lancet. Diabetes & endocrinology
Chapter : Section3
Journal Year : 2017
Cited by : Not Available

BACKGROUND: Semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue, suitable for once-weekly subcutaneous administration, in development for treatment of type 2 diabetes. We assessed the efficacy and safety of semaglutide versus the dipeptidyl pe.....

Keywords : ["onceweekly semaglutide versus oncedaily sitagliptin", "doubleblind phase randomise trial", "type diabetes sustain", "metformin thiazolidinedione", "safety", "patient", "efficacy", "addon"]